Loading...
•
Jun 30, 2024
Ocugen Q2 2024 Earnings Report
Reported second quarter 2024 financial results and provided a business update.
Key Takeaways
Ocugen reported second quarter 2024 financial results, highlighting progress in their modifier gene therapy platform, including dosing patients in the OCU400 Phase 3 clinical trial and advancing OCU410 into Phase 2. They also received $32.6 million net cash from a public offering, extending their cash runway into Q3 2025.
Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial.
OCU410 preliminary safety and efficacy data expected later this year.
Expanded access program approved for OCU400.
Received $32.6 million net cash from underwritten public offering of common stock.
Ocugen
Ocugen
Forward Guidance
Ocugen expects the cash runway to extend into the third quarter of 2025.